 |
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2010, vol. 16, book 3
Subject Collection: Medicine
Page: 74 - 77
DOI: 10.5272/jimab.1632010_74
Online date: March 18, 2011
CAPECITABINE AND IRINOTECAN AS FIRST- LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
Deyan Davidov,
Department of Chemotherapy, Oncological Center, Medical University, Pleven, Bulgaria
ABSTRACT:
Objectives: Capecitabine is an oral fluoropyrimidine carbamate that is at least as effective than Fluorouracil / Leucovorin as first- line treatment for patients with metastatic colorectal cancer /CRC/. The topoisomerase I inhibitor Irinotecan has shown consistent efficacy in chemotherapy- naive patients. The aim of this study was to determine the efficacy and tolerability of Capecitabine in combination with Irinotecan /XELIRI/ as first- line therapy in patients with advanced CRC. Methods: In the period 2007- 2009 twenty-one consecutive patients with metastatic CRC entered the study. The treatment schedule consists of Capecitabine 1250 mg/m2 p.o. twice daily for 14 days with a 7- day rest period and intravenous Irinotecan 180mg/m2 day 1 with repetition of courses every 21 days. Results: Overall response rate was 33,3%. Median time to progression and overall survival was 7,6 months and 15,6 months, respectively. The most common grade 3- 4 adverse events were diarrhea and neutropenia. There were no treatment- related deaths. Conclusion: These results indicate that XELIRI is a potentially feasible and clinically active regimen in patients with advanced CRC.
Key words: Relapsed small cell lung cancer, Second- line treatment, Intravenous Topotecan, Survival.
Page: 74-77; FULL TEXT PDF (120 KB) Abstract
REFERENCES:
1. Ferlay J, Tiwari RC, Murray T. et al, Cancer Statistics, 2004. CA Cancer J Clin, 2004;54: 8–29
2. Benson AB 3rd: Therapy for advanced colorectal cancer. Semin Oncol, 1998 Oct; 25(5 Suppl 11):2-11 [PubMed]
3. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol, 1998 Jan;16(1):301-308 [PubMed]
4. Thirion P., Wolmark N, Haddad E. Buyse M, Piedbois P. Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer. Ann Oncol, 1999 Nov; 10(11):1317- 1320 [PubMed]
5. Pommier Y, Tanizava A, Kohn KW. Mechanisms of topoisomerase I inhibition by anticancer drugs. In: Liu LF, ed. Advanced in pharmacology. New York: Academic Press 1994; 29B; 73-92
6. Meropol NJ: Oral fluoropyrimidines in the treatment of colorectal cancer. Eur J Cancer, 1998; 34:1509-1513
7. Ishikawa T, Utoh M, Sawada N, et al: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol, 1998; 55:1091-1097
8. Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer, 1998; 34:1274-1281
9. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, et al: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol, 1998 Sep;16(9):2977-2985 [PubMed]
10. Schuller J, Cassidy J, Dumont E, et al: Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol, 2000; 45:291-297
11. Delord JP, Pierga JY, Dieras F. Bertheault-Cvitkovic F, Turpin FL, Lokiec F, et al, A phase I clinical and pharmacokinetic study of capecitabine /Xeloda/ and irinotecan combination therapy /XELIRI/ in patients with gastrointestinal tumours, Br J Cancer, 2005 Mar;92(5): 820- 826 [PubMed]
12. Miller AB, Hoogstraten B, Staquet M et al, Reporting results of cancer treatment. Cancer 1981; 47; 207-214
13. Brimdage MD, Pater JL, Zee B, Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 1993; 85; 38-48
14. Kaplan EL, Meyer P, Non- parametric estimation from incomplete observations, J Am Stat Assoc 1959; 53; 457- 481
15. Gill Sharlene, Treatment of metastatic colorectal cancer, Oncol Exch, 2005; 5: 6- 9